Quarterly report · Q2
4575.TEDINET S100SSAJ
Period2023-07-01 → 2023-12-31
Filed2024-02-09
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 41
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Operating income | −¥387m | 2023-07-01 → 2023-12-31 | Standalone | Operating income |
| Operating income | −¥552m | 2022-07-01 → 2022-12-31 | Standalone | Operating income |
| Ordinary income | −¥393m | 2023-07-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2022-07-01 → 2023-06-30 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥563m | 2022-07-01 → 2022-12-31 | Standalone | Ordinary income |
| Profit before tax | −¥393m | 2023-07-01 → 2023-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥563m | 2022-07-01 → 2022-12-31 | Standalone | Income before income taxes |
| Net income | −¥394m | 2023-07-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2022-07-01 → 2023-06-30 | Standalone | Net income loss (5-year summary) |
| Net income | −¥563m | 2022-07-01 → 2022-12-31 | Standalone | Profit loss |
| Total assets | ¥3.3bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥2.1bn | at 2023-06-30 | Standalone | Assets |
| Total assets | ¥2.0bn | at 2022-12-31 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥121m | at 2023-12-31 | Standalone | Liabilities |
| Total liabilities | ¥154m | at 2023-06-30 | Standalone | Liabilities |
| Net assets / equity | ¥3.2bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2023-06-30 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2022-12-31 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.8bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.6bn | at 2023-06-30 | Standalone | Cash and deposits |
| Cash & equivalents | ¥2.8bn | at 2023-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.0bn | at 2022-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥738m | at 2022-06-30d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥374m | 2023-07-01 → 2023-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2022-07-01 → 2023-06-30 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥556m | 2022-07-01 → 2022-12-31 | Standalone | Net cash provided by used in operating activities |
| Financing cash flow | ¥1.5bn | 2023-07-01 → 2023-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.3bn | 2022-07-01 → 2023-06-30 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.8bn | 2022-07-01 → 2022-12-31 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-22.37 | 2023-07-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-11.18 | 2023-10-01 → 2023-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-83.03 | 2022-07-01 → 2023-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-40.12 | 2022-07-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-15.84 | 2022-10-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 95.4% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.0% | at 2023-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.8% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 18,023,000 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,395,000 | at 2023-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 15,839,000 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 316
| Item | Context | Value | Unit |
|---|---|---|---|
| Quarterly balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding research and development expenses (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes segment information etc quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that companys business comprises single segment | CurrentYTDDuration_NonConsolidatedMember | Original text (Japanese)当社は、医薬品事業の単一セグメントであるため、記載を省略しています。 | |
| Notes per share information quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |